IBDEI10Z ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16484,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,16485,0)
 ;;=C82.90^^88^879^76
 ;;^UTILITY(U,$J,358.3,16485,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16485,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,16485,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,16485,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,16486,0)
 ;;=R59.1^^88^879^61
 ;;^UTILITY(U,$J,358.3,16486,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16486,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,16486,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,16486,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,16487,0)
 ;;=C91.40^^88^879^80
 ;;^UTILITY(U,$J,358.3,16487,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16487,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,16487,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,16487,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,16488,0)
 ;;=C91.42^^88^879^78
 ;;^UTILITY(U,$J,358.3,16488,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16488,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,16488,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,16488,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,16489,0)
 ;;=C91.41^^88^879^79
 ;;^UTILITY(U,$J,358.3,16489,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16489,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,16489,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,16489,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,16490,0)
 ;;=D57.01^^88^879^81
 ;;^UTILITY(U,$J,358.3,16490,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16490,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,16490,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,16490,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,16491,0)
 ;;=D57.00^^88^879^82
 ;;^UTILITY(U,$J,358.3,16491,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16491,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,16491,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,16491,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,16492,0)
 ;;=D57.02^^88^879^83
 ;;^UTILITY(U,$J,358.3,16492,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16492,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,16492,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,16492,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,16493,0)
 ;;=D68.32^^88^879^85
 ;;^UTILITY(U,$J,358.3,16493,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16493,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,16493,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,16493,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,16494,0)
 ;;=C22.2^^88^879^86
 ;;^UTILITY(U,$J,358.3,16494,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16494,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,16494,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,16494,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,16495,0)
 ;;=D58.9^^88^879^88
 ;;^UTILITY(U,$J,358.3,16495,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16495,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,16495,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,16495,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,16496,0)
 ;;=C81.99^^88^879^89
 ;;^UTILITY(U,$J,358.3,16496,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16496,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,16496,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,16496,2)
 ;;=^5001460
